Phase 1b / 2, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of B-701 plus docetaxel compared to placebo plus docetaxel in the treatment of locally advanced or metastatic urothelial carcinoma in patients with relapse after treatment reference or who have not responded to this
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: BIOCLIN THERAPEUTICS INC
- Phase: II
- Execution start: 01/03/2018
- End of execution: 31/12/2021
- PI: RAQUEL LUQUE CARO